Movano Inc. (Nasdaq: MOVE) — Form 10-Q Summary
Entity note: The supplied filing is for Movano Inc., doing business as Movano Health—not Corvex, Inc. It covers the three months ended March 31, 2024 and was signed May 17, 2024. Financial statement amounts below are in millions unless otherwise noted.
Business context and reporting period
Movano is an early-stage health technology company developing consumer and medical wearables. Its Evie Ring, launched in November 2023 as a general-wellness device, began generating recognized revenue in Q1 2024 as customer deliveries commenced. The company is also developing the Evie Med Ring and technology intended to support glucose and cuffless blood-pressure monitoring.
Financial performance and liquidity
| Metric | Q1 2024 | Q1 2023 |
|---|---|---|
| Revenue | $0.852 | $0 |
| Cost of revenue | $1.215 | $0 |
| Gross profit (loss) | $(0.363) | $0 |
| Research and development | $2.887 | $3.894 |
| Sales, general and administrative | $2.504 | $3.309 |
| Operating loss | $(5.754) | $(7.203) |
| Net loss | $(5.720) | $(7.096) |
| Basic and diluted loss per share | $(0.10) | $(0.19) |
| Net cash used in operations | $(4.131) | $(6.080) |
Q1 2024 gross margin was approximately negative 42.6%, reflecting costs exceeding initial sales. Cash and cash equivalents fell to $2.145 at March 31, 2024 from $6.118 at year-end 2023. Current assets were $4.445 versus current liabilities of $6.569; stockholders’ deficit was $1.478. No conventional borrowings are disclosed; lease liabilities were approximately $0.208 in total. The filing states that quarter-end cash was not expected to fund operations for the following 12 months.
Material changes versus the prior comparable period
- Revenue began in Q1 2024, with $0.852 recognized from Evie Ring products and related elements; Q1 2023 had no revenue.
- Research and development expense decreased 26% and SG&A decreased 24%, primarily due to lower research-related spending and reduced headcount and related costs.
- Net loss improved by $1.376, while operating cash use improved by $1.949. Cash nonetheless declined by $3.973 during the quarter.
- Shares outstanding increased to 56.1 million from 55.8 million at December 31, 2023; the company sold 273,307 shares through its ATM program for approximately $0.2 million net.
Outlook, risks, contingencies and unusual items
- Going concern: The company reported an accumulated deficit of $130.1 million and concluded that substantial doubt exists about its ability to continue as a going concern within one year after issuance of the financial statements. It expects further losses and needs additional financing; unavailable or unfavorable funding could force delays, reductions or cessation of programs.
- Subsequent financing: A private placement closed April 5, 2024, raising approximately $24.1 million gross, before approximately $1.4 million in fees and expenses. It involved 45.3 million units, each including common stock or a pre-funded warrant and a warrant; this creates substantial potential dilution. The company also reported extending certain placement warrants in May.
- Product and regulatory outlook: The company withdrew its initial 2023 FDA 510(k) submission for the Evie Med pulse-oximeter ring, citing device changes and additional FDA requirements. It resubmitted in April 2024 after a second pivotal hypoxia trial and expected an FDA decision in July 2024. The filing gives no revenue or profitability guidance.
- Other risks: The company depends on third-party manufacturers and suppliers. A vendor royalty commitment has a maximum stated amount of approximately $6.1 million, subject to reductions for specified research and development payments; royalties for Q1 were not significant. Management reported no material litigation or non-cancelable contractual commitments.
- Controls: Disclosure controls were deemed ineffective as of March 31, 2024 because of a previously identified material weakness involving financial close and reporting controls, account reviews and analyses, and certain IT general controls. Remediation efforts were ongoing.
Most important facts for investors to verify
- Confirm the filing’s registrant identity: the source document is Movano Inc., not Corvex, Inc.
- Review the April private placement’s final net proceeds, share and warrant terms, and resulting fully diluted share count.
- Track cash burn, available financing, and management’s ability to address the disclosed going-concern uncertainty.
- Verify the FDA review status and timing for the Evie Med submission, and assess Evie Ring sales, returns, and product-level costs.
- Monitor remediation of the material weakness and any subsequent changes in financial reporting controls.